Kodiak Sciences is a biopharmaceutical company committed to researching, developing and commercializing next-generation therapies for retinal diseases

OUR MISSION

Kodiak aims to prevent and treat the leading causes of blindness in the developed world

TRAILBLAZING SCIENCE

OUR CREATIVE AND THOUGHTFUL FOUNDATION

“GO-TO” MEDICINES

OUR CHALLENGE TO THE STATUS QUO

SINGULAR FOCUS IN OPHTHALMOLOGY

OUR 24/7/365

OUR PRODUCT CANDIDATES

Three late-phase candidates advancing in parallel, collectively addressing the limitations of today’s therapies across a broad spectrum of retinal diseases

Tarcocimab Tedromer

High-prevalence retinal
vascular diseases

Wet AMD
Diabetic retinopathy
Retinal vein occlusion

Phase 3

KSI-501

High-prevalence retinal
vascular diseases

Indications of interest include wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy

Phase 3

KSI-101

Macular edema
secondary to inflammation (MESI)

Phase 3

Explore our pipeline →

Slide

Tarcocimab tedromer

Anti-VEGF ABC^®
High-prevalence retinal vascular diseases

Tarcocimab is our most advanced program with three Phase 3 studies complete and two ongoing.

Tarcocimab is an anti-VEGF Antibody Biopolymer Conjugate (ABC) being developed to provide strong immediacy and high durability at the same time in a single biologic. Across multiple studies, tarcocimab demonstrated consistent 6-month predominant durability and favorable safety. With a flexible 1-month through 6-month label, we believe tarcocimab can be the “mainstay” intravitreal biologic for all patients. Learn more

Tarcocimab is our most advanced program with three Phase 3 studies complete and two ongoing.

Slide

KSI-501

Bispecific anti-IL-6, VEGF trap ABC^®
High-prevalence retinal vascular diseases

KSI-501 is a first-in-class, bispecific Antibody Biopolymer Conjugate (ABC) designed to address two key unmet needs – higher efficacy and higher durability – by targeting retinal inflammation and vascular permeability simultaneously.

The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases. Learn more

Slide

KSI-101

Bispecific anti-IL-6, VEGF trap protein
Macular edema secondary to inflammation (MESI)

KSI-101 is first-in-class, potent 100 mg/mL high-strength bispecific protein being developed for the treatment of macular edema secondary to inflammation (MESI).

Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying disease mechanisms of IL-6-mediated inflammation and edema, and VEGF-mediated vascular permeability. Learn more

KSI-101 is first-in-class, potent 100 mg/mL high-strength bispecific protein being developed for the treatment of macular edema secondary to inflammation (MESI).

Slide

Best of both worlds

A science of high immediacy and high durability at the same time in a single biologic for high prevalence retinal vascular diseases

Tarcocimab and KSI-501 are designed to bring the best of both worlds, a science of high immediacy and high durability at the same time in a single biologic for high prevalence retinal vascular diseases

THE ABCD OF OUR SCIENCE

We are bringing new science to the design and development of next generation retinal medicines. Our Antibody Biopolymer Conjugate Drug (ABCD) Platform uses a bio-inspired polymer to enable multi-modal, multi-mechanistic treatment of complex ocular and systemic diseases

Antibody Biopolymer Conjugate Drug

Biopolymer

Built-in durability

Designed to target multiple intracellular and extracellular mechanisms simultaneously

Designed for ocular and systemic diseases

Built-in durability

Designed to target multiple intracellular and extracellular mechanisms simultaneously

Designed for ocular and systemic diseases

Learn more about the science of our ABCD Platform →

OUR CULTURE AND VALUES

We are actively building a place, our Kodiak Village, where we are inspired, where we feel valued, and where we can grow our personal and professional journeys while advancing our mission. Historically referred to within Kodiak as the 4 C’s, our values are: